Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Advanced Solid Tumors 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Solid Tumors 1Solid Malignancies 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Leukemia 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × ST 1481 × Clear all
NCT00032903 2009-06-03

This is an Early Study to Investigate the Effect of GimatecanĀ® in Adults With Malignant Glioma.

Sigma-Tau Research, Inc.

Phase 1/2 Completed
59 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚔